Gonal-f RFF Redi-ject

EMD Serono, Inc.🇺🇸 United States

FDA Page

Effective Date: Feb 2, 2022
Approval ID: b6d11c45-b502-478e-bb28-2ff596ea259c
Products: 3 registered
Version: 10

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use Gonal-f RFF Redi-ject safely and effectively. See full prescribing information for Gonal-f RFF Redi-ject Gonal-f RFF* Redi-ject (follitropin alfa injection) for subcutaneous use *revised formulation female Initial U.S. Approval: 1997

Quick Stats

Total Products3

Labelers2

Label Sections22

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.